Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03681548
Other study ID # LC-101-02
Secondary ID 0384-18CTRI/2018
Status Completed
Phase Phase 1
First received
Last updated
Start date August 29, 2018
Est. completion date March 7, 2019

Study information

Verified date November 2019
Source Ayana Pharma Ltd.,
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .


Description:

This study is a randomized, open label, two arm, single dose, crossover bioequivalence study. This study will be conducted in female subjects aged 18 to 65 years diagnosed with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with Doxorubicin Hydrochloride Liposome Injection product. Each subject will be randomized to one of the two treatment sequences (RT or TR) according to a randomization scheme prepared prior to start of the trial. Serial blood samples for determination of free and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle., This study has an adaptive 2-stage design. A sufficient number of subjects with ovarian cancer shall be recruited to have approximately 42 evaluable subjects completing all follow up procedures (Stage 1). An interim analysis of free and encapsulated doxorubicin will be performed at the end of Stage 1. If the bioequivalence of encapsulated and free doxorubicin has been established, then the study will be stopped. Otherwise, the study may continue into Stage 2 with additional number of ovarian cancer subjects. A final evaluation of bioequivalence based on free and encapsulated doxorubicin will be performed at the end of Stage 2 and will include all enrolled subjects completing the study. Bioequivalence criteria: the 94.12% confidence interval of the ratio of geometric means of TEST to REFERENCE for Cmax, AUC0-t, AUC0-∞, for free and encapsulated doxorubicin should be between 80.00% and 125.00%.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date March 7, 2019
Est. primary completion date February 8, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Adult female subjects between 18 to 65 years of age (both inclusive) at the time of screening visit.

2. Subjects with histologically or cytological proven ovarian cancer, whose disease has progressed or recurred after platinum-based chemotherapy and scheduled to start therapy with or who are already receiving an approved dose of 50 mg per meter square Doxorubicin Hydrochloride Liposome Injection product.

3. Subjects expected to be able to receive both doses of Doxorubicin Hydrochloride Liposome Injection.

4. Subjects eligible for receiving a dose of 50 mg per meter square of Doxorubicin Hydrochloride Liposome Injection.

5. Subjects with Performance less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) performance scale

6. Cardiac function (LVEF) greater than or equal to 50 percentage.

7. Adequate renal, hepatic and bone marrow function without blood product or hematopoietic growth factor support.

8. Subjects able to understand the investigational nature of this study.

9. Availability of subject for the entire study period and willingness to adhere to protocol requirements.

10. For subjects of child-bearing potential, serum beta HCG pregnancy test at screening and urine pregnancy test prior to dosing must be negative and subjects agree to use an acceptable and effective approved method of contraception

11. Subjects of non-childbearing potential who are either surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or greater than 1 year postmenopausal with follicle stimulating hormone in the postmenopausal range

12. Signed written informed consent.

Exclusion Criteria:

1. Subjects with history or presence of significant:

- Allergy or significant history of hypersensitivity or idiosyncratic reactions to a conventional formulation of Doxorubicin Hydrochloride and/or any components of Doxorubicin Hydrochloride liposome injection.

- Clinically significant pulmonary, hepatic, renal, bone marrow, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

- Impaired cardiac function

2. Alcohol dependence, alcohol abuse or drug abuse or addiction with any recreational drug within the past one year.

3. Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, p. carinii or other microorganism (bacterial, viral or fungal).

4. Clinically significant illness (except ovarian cancer) within four weeks prior to dosing.

5. Prior radiation therapy to mediastinum

6. Concomitant use of other cytotoxic or cytostatic drugs or of radiotherapy within four weeks prior to dosing

7. Subject under treatment of myelotoxic drugs, other than doxorubicin (liposomal).

8. Use of prescription or non-prescription herbal and dietary supplements, within 7 days prior to dosing.

9. Subjects with other known active malignancies requiring treatment within 3 years (except for ovarian and/or skin cancer).

10. Subjects with known brain metastasis and/or subjects considered for radiotherapy treatment.

11. Positive result to any of the following: HIV-1/2, hepatitis A, B and C; syphilis.

12. Use of CYP3A4 enzyme-modifying drugs in the previous 30 days prior to dosing and during the study

13. Subjects who have:

- Systolic blood pressure less than 90 mmHg or more than 160 mmHg

- Diastolic blood pressure less than 60 mmHg or more than 95 mmHg

- Pulse rate below 55 per min. or above 100 per min14.

14. Subjects with abnormal laboratory parameters

15. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s).

16. Subjects who are legally detained in an official institute.

17. Subjects with prior doxorubicin exposure that would result in a total lifetime exposure of 550 mg per meter square or more after four cycles of treatment.

18. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments

19. Females of childbearing potential unwilling to use acceptable contraception (as identified in the protocol) throughout the trial and for 6 months after the last dose of study drug.

20. Pregnant or breast-feeding subjects.

Study Design


Intervention

Drug:
Doxorubicin Hydrochloride Liposome Injection
50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation

Locations

Country Name City State
India Sparsh Hospitals & Critical Care (P) Ltd. Bhubaneshwar Odisha
India Saveetha Medical College & Hospital Chennai Tamil Nadu
India Sri Ramachandra Medical Centre Chennai Tamil Nadu
India VGM Hospital Coimbatore Tamil Nadu
India MNJ Institute of Oncology & Regional Cancer Center Hyderabad Andhra Pradesh
India K R Hospital Mysore Karnataka
India Apex Wellness Rishikesh Hospital Nashik Maharashtra
India HCG Manavata Cancer Centre Nashik Maharashtra
India Noble Hospital Pvt Ltd. Pune Maharashtra
India Nirmal Hospital Pvt. Ltd. Surat Gujarat
India Unique Hospital - Multispeciality and Research Institute Surat Gujarat
India Aman Hospital and Research Center Vadodara Gujarat
India Kailash Cancer Hospital And Research Center Vadodara Gujarat
India HCG City Cancer Centre Vijayawada Andhra Pradesh
India Mahatma Gandhi Cancer Hospital & Research Institute Visakhapatnam Andhra Pradesh

Sponsors (2)

Lead Sponsor Collaborator
Ayana Pharma Ltd., Lambda Therapeutic Research Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of bioequivalence using Cmax of encapsulated and free doxorubicin in plasma Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using maximum plasma doxorubicin concentration (Cmax) of encapsulated and free doxorubicin measurements in plasma. Throughout 15 days after both dosing.
Primary Assessment of bioequivalence using AUC (0-t) of encapsulated and free doxorubicin in plasma Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation (AUC 0-t) of encapsulated and free doxorubicin measurements in plasma. Throughout 15 days after both dosing.
Primary Assessment of bioequivalence using AUC (0-inf) of encapsulated and free doxorubicin in plasma Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using areas under the plasma concentration versus time curve calculated from 0 to infinity (AUC 0-inf) of encapsulated and free doxorubicin measurements in plasma. Throughout 15 days after both dosing.
Secondary Assessment of bioequivalence using Cmax of total doxorubicin in plasma Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using Cmax of total doxorubicin measurements in plasma. Throughout 15 days after both dosing.
Secondary Assessment of bioequivalence using AUC (0-t) of total doxorubicin in plasma Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using AUC (0-t) of total doxorubicin measurements in plasma. Throughout 15 days after both dosing.
Secondary Assessment of bioequivalence using AUC (0-inf) total doxorubicin as secondary analyte Assessment of bioequivalence of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product). Bioequivalence will be assessed using AUC (0-inf) of total doxorubicin measurements in plasma. Throughout 15 days after both dosing.
Secondary Assessment of safety Assessment of incidence of adverse events Troughout 42 days after first dosing
See also
  Status Clinical Trial Phase
Recruiting NCT06014528 - IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Recruiting NCT03717610 - Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer N/A
Active, not recruiting NCT04175470 - Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer Phase 2
Recruiting NCT03983226 - Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Phase 2
Recruiting NCT05095558 - Microtransplantation for Ovarian Cancer Phase 1/Phase 2
Completed NCT03657966 - DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Not yet recruiting NCT06102707 - The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients N/A
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Withdrawn NCT04149145 - Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer Phase 1
Completed NCT01332656 - Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel Phase 2
Completed NCT01111903 - A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse Phase 1/Phase 2
Recruiting NCT03734692 - Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Phase 1/Phase 2
Recruiting NCT03827837 - Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors Phase 2
Not yet recruiting NCT05990192 - SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Phase 2
Completed NCT01485848 - EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer Phase 2
Recruiting NCT04072263 - Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2